Home / News / Pearce IP Blog
Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement...
Originally published in the IAM Saturday Opinion on 11 September 2021. Australia was recently thrust into the global...
Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an...
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when...
The Australian Federal Court in Thaler v Commissioner of Patents [2021] FCA 879 (30 July 2021) has determined that an...
Pearce IP recently reported on the Full Court of the Federal Court decision in Ariosa Diagnostics, Inc v Sequenom, Inc...
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia On 18 June 2021, the Full...
In September 2020, Pearce IP reported on a significant Australian Patent Office decision, which held that a patent...
Pearce IP recently reported on recommendations made by an independent review into the Australian patent system to...
At the end of 2020, we reported on a Government review of the Australian patent system and its accessibility for small...
As a second wave of COVID-19 ravages India, the rest of the world should be paying close attention to the reported...
Background In October 2020, the Australian Government announced a $1.5 billion investment in a Modern Manufacturing...
The Australian Patent Office, in Ono Pharmaceutical Co., Ltd. et al [2020] APO 43, has emphatically confirmed that a...
First published in Australian Intellectual Property Law update Vol. 33, No. 2, Jun 2020: 35-38 The COVID-19 pandemic...
His scholarship focuses on philosophy and the history of ideas. His published works include: “Plotinus, Self and the...
The enlarged bench of the Full Court of the Australian Federal Court has clarified what constitutes infringement of...